ArticleClinical and experimental medicine2025
Transcriptomic landscape of generalized pustular psoriasis before and after acitretin/glucocorticoids treatment.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.International journal of molecular sciences · 2026Review
- Vunakizumab and Acitretin for Elderly Refractory Generalized Pustular Psoriasis: A Case Report and Comprehensive Literature Review.Biologics : targets & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized pustular psoriasis (GPP) is a rare and severe subtype of psoriasis, characterized by sterile pustules on the skin surface. Acitretin is currently one of the first-line treatments for GPP, while glucocorticoids are commonly used in patients with hyperpyrexia. However, the pathogenesis of GPP and the mechanisms of these drugs need to be further clarified. The clinical characteristics of GPP before and after treatment were collected and compared using student t tests or paired Wilcoxon tests. We analyzed the transcriptomic features of GPP using publicly available sequencing data. Subsequently, RNA sequencing of peripheral blood mononuclear cells (PBMCs) from 29 GPP patients before and after treatment was conducted. The patients were divided into one group treated with acitretin alone (n = 25) and the other group treated with a combination of glucocorticoids (n = 4). Potential related genes were further validated using qRT-PCR in additional 17 patients. We observed that inflammatory signaling pathways were significantly upregulated in GPP and decreased after treatment, consistent with the reductions in inflammatory markers such as PGA scores, C-reactive protein (CRP) and neutrophil counts following treatment. Specifically, the expressions of several critical inflammation-related genes, such as CD14, CTSL, CEBPD, and IL1B, significantly decreased after treatment. Besides, compared to monotherapy with acitretin, the combination of acitretin with glucocorticoids can significantly reduce the expression of genes related to immune cell chemotaxis and activation. Acitretin can significantly reduce the inflammatory response of GPP patients. Combined use of glucocorticoids further reduces the expression of genes related to immune cell chemotaxis and activation. Key genes from these pathways are potential targets for developing novel treatment of GPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.